168 related articles for article (PubMed ID: 26232855)
1. A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer.
Ohnuma H; Sato Y; Hirakawa M; Okagawa Y; Osuga T; Hayashi T; Sato T; Miyanishi K; Kobune M; Takimoto R; Sagawa T; Hori M; Someya M; Nakata K; Sakata K; Takayama T; Kato J
Int J Radiat Oncol Biol Phys; 2015 Oct; 93(2):382-90. PubMed ID: 26232855
[TBL] [Abstract][Full Text] [Related]
2. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
Miyazaki T; Ojima H; Fukuchi M; Sakai M; Sohda M; Tanaka N; Suzuki S; Ieta K; Saito K; Sano A; Yokobori T; Inose T; Nakajima M; Kato H; Kuwano H
Ann Surg Oncol; 2015 Oct; 22(11):3653-8. PubMed ID: 25691281
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II study of docetaxel, cisplatin, and 5-fluorouracil combination chemoradiotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2015 Mar; 75(3):449-55. PubMed ID: 25544126
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant chemotherapy with docetaxel, nedaplatin, and fluorouracil for resectable esophageal cancer: A phase II study.
Ohnuma H; Sato Y; Hayasaka N; Matsuno T; Fujita C; Sato M; Osuga T; Hirakawa M; Miyanishi K; Sagawa T; Fujikawa K; Ohi M; Okagawa Y; Tsuji Y; Hirayama M; Ito T; Nobuoka T; Takemasa I; Kobune M; Kato J
Cancer Sci; 2018 Nov; 109(11):3554-3563. PubMed ID: 30137686
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
Guo JF; Zhang B; Wu F; Wang B; Xing H; Zhu GY; Nie XY; Peng J
Chin J Cancer; 2010 Mar; 29(3):321-4. PubMed ID: 20193118
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer.
Ueda S; Kawakami H; Nishina S; Sakiyama T; Nonagase Y; Okabe T; Tamura T; Nakagawa K
Cancer Chemother Pharmacol; 2015 Aug; 76(2):279-85. PubMed ID: 26050210
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).
Kato K; Muro K; Minashi K; Ohtsu A; Ishikura S; Boku N; Takiuchi H; Komatsu Y; Miyata Y; Fukuda H;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):684-90. PubMed ID: 20932658
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose-escalation study of docetaxel, nedaplatin, and 5-fluorouracil combination chemotherapy in patients with advanced esophageal cancer.
Miyazaki T; Sohda M; Tanaka N; Suzuki S; Ieta K; Sakai M; Sano A; Yokobori T; Inose T; Nakajima M; Fukuchi M; Ojima H; Kato H; Kuwano H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):853-7. PubMed ID: 23306309
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil for esophageal cancer.
Emi M; Hihara J; Hamai Y; Aoki Y; Okada M; Kenjo M; Murakami Y
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1499-505. PubMed ID: 22382882
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and feasibility of ambulatory treatment-based monthly nedaplatin plus S-1 in definitive or salvage concurrent chemoradiotherapy for early, advanced, and relapsed esophageal cancer.
Yamashita H; Haga A; Takenaka R; Kiritoshi T; Okuma K; Ohtomo K; Nakagawa K
Radiat Oncol; 2016 Jan; 11():4. PubMed ID: 26781439
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
Higuchi K; Koizumi W; Tanabe S; Sasaki T; Katada C; Ishiyama H; Hayakawa K
Radiother Oncol; 2008 Jun; 87(3):398-404. PubMed ID: 18405987
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
